EVI Industries stock price target maintained at $28 by DA Davidson

EVI Industries Inc (EVI) shares rose 8.5% after its board approved a share repurchase program authorizing buybacks of up to $10 million of outstanding common stock. Repurchases may occur via open-market or negotiated transactions, including Rule 10b5-1 plans, at management’s discretion. The program has no expiration and can be modified or terminated.

EVI Industries agreed to acquire privately held Sudsies, Inc. to launch a consumer garment care division. EVI said the deal should close promptly and be accretive to FY ending June 30, 2027. Sudsies reported about $21.7M revenue and $4.7M operating income for the 12 months ended June 30, and EVI shares closed at $16.52.

The article cites three long-term drivers for uranium stocks: World Nuclear Association projects global uranium demand up about 28% by 2030; Mining.com says output from existing mines could be cut in half after 2030, requiring new supply; and the Trump administration added uranium to the U.S. critical minerals list. Eastport Critical Metals reported assay results from its Foley project in Botswana, including uranium mineralisation (>200 ppm U3O8) in 6 of 10 RC holes over a 1.4 km strike length.

RTX Corporation (RTX) is benefiting from increased defense spending, securing contracts worth billions for missiles and air-defense systems. The company's defense backlog stands at $119 billion, with a book-to-bill ratio of 2.4, indicating strong future demand. However, challenges in converting backlog to profits and managing costs remain. Hedge funds have increased their stakes, while short interest is low. RTX stock is up 9% year-to-date.

Morgan Stanley maintains an Overweight rating and $90 price target for Carvana (CVNA), citing durable sales growth, underrated free cash flow, and cost savings. The stock is near $74, down 7% YTD, despite strong Q2 performance. Analyst Daniela Haigian expects high 30% sales growth in H2, limited by supply, not demand. Gross profit per unit fell 6% in Q2 but is expected to stabilize by 2030.

CVS Health launched updated flu vaccines nationwide, aiming to boost pharmacy traffic and healthcare revenues. Analysts rate it 'Strong Buy' with a $114.25 price target, implying a 17.5% upside. Rival UnitedHealth Group has underperformed with 21.5% YTD and 30.2% 52-week gains.